AXL and breast carcinoma: Despite the elevated levels of AXL seen in breast malignancies, less than 2.5% of breast cancers exhibit any alteration in AXL (mutation, rearrangement, etc.), and amplifications specifically are also exceedingly rare (less than 2%) [41–43].